Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy Technology 6/24/2025
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
View this post in the Community →
Similar Community Posts Join
6 / 231 resultscommunity Il PP405 è molto promettente ma non è l'unico in grado di liberarci dalla iattura
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
community PP405 is a game changer. One for the history books. Era defining moment and Pelage know it.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
community New Study: PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and stimulate natural hair growth by 20%
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
community PP405 vs Hair Cloning – Which Would Be Better for NW7 to NW1?
community PP405 bandwagon, time to resume the hype train.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
Related Research
6 / 26 results
research Review of the 2024 American Academy of Dermatology Annual Meeting
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Use of Vitamins and Minerals in the Treatment of Hair Loss: A Cross-Sectional Survey Among Dermatologists in Saudi Arabia
Many dermatologists in Saudi Arabia recommend vitamins and minerals for hair loss, often based on personal experience rather than strong evidence.
research British Association of Dermatologists' Guidelines for the Management of Tinea Capitis 2014
Accurate diagnosis and effective oral treatment are key to managing tinea capitis and preventing its spread.
research Estrogen Functions in Skin and Skin Appendages
Oestrogens help maintain healthy skin, heal wounds, and may protect against skin aging and cancer.
research Bioengineered Plants as a Source of Omega-3 Fatty Acids
Genetically modified plants could be an important source of omega-3 fats to meet global needs.